Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug. Read the latest pharma headlines in today's…
Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug. Read the latest pharma headlines in today's…
<iframe src="https://statesidedaily.com/embed/cluster/4b97bbcf9701463d29d4e5e32c0352b8f229bea1" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more"></iframe>
